However, their interpretation remains somewhat limited by substantial variability in detection assays, differences in scoring protocols, including tumor-cell vs. immune-cell scoring, PD-L1 protein Tumor Proportion Score (TPS) vs. Combined Positive Score (CPS), and inconsistent thresholds for defining positivity, which hinders reliable comparison across the different studies [219,222]. The gene discussed is CD274; the disease is neoplasm.